European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Assets

brenipatide (LY3537031)

Lilly

Molecule class
NOT VERIFIED. No pharmacology source read. Confirmed only that it matches none of our fourteen psychedelic count terms and is not BPL-003 or VLS-01.
Phase
Phase 3 in MDD (two pivotals) and alcohol use disorder (two pivotals); Phase 2 in bipolar disorder, IBS-D, IBS-C and asthma (CTIS 2025-522640-41-00, 52-week, authorised DE and FR 2026-01-21, PL 2026-01-30, NL 2026-02-02; recruitment started PL 2026-02-18)
Indication
major depressive disorder; alcohol use disorder; bipolar disorder; irritable bowel syndrome (IBS-D, IBS-C); uncontrolled moderate to severe asthma
Sponsor geography
US
Next catalyst
NCT07775300 moves to RECRUITING; resolves the Issue 11 call, by 2026-12-31
IP status
Not checked. Recorded as unchecked rather than left blank.

The catalyst above is recorded as inferred, not verified. It is this publication's reading of the company's guidance, not a date the company has published.

euclinicaltrials.euregistryverified 2026-09-15

Registered trials

  • NCT07286175ClinicalTrials.gov

    PHASE2 · Bipolar Disorder · RECRUITING · Argentina, Brazil, China, India, Japan, Mexico, Puerto Rico, United States

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT07412756ClinicalTrials.gov

    PHASE3 · Depressive Disorder, Major · RECRUITING · Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-11-07

  • NCT07775300ClinicalTrials.gov

    PHASE3 · Depressive Disorder, Major · RECRUITING · Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland, Puerto Rico, South Korea, Spain, Taiwan, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-10-19

  • 2025-522310-24-00CTIS

    Therapeutic confirmatory (Phase III) · Depressive Disorder, Major · Authorised · Germany, Greece, Poland, Spain

    euclinicaltrials.euctis registryverified 2026-10-19

  • 2025-522312-16-00CTIS

    Therapeutic confirmatory (Phase III) · Alcohol Use Disorder · Authorised · Belgium, Germany

    euclinicaltrials.euctis registryverified 2026-11-07

  • 2025-522313-38-00CTIS

    Therapeutic confirmatory (Phase III) · Alcohol Use Disorder · Authorised · Belgium, Germany

    euclinicaltrials.euctis registryverified 2026-08-31

  • 2025-524973-17-00CTIS

    Therapeutic exploratory (Phase II) · Irritable Bowel Syndrome Diarrhea · Authorised · Belgium, Germany, Poland, Spain

    euclinicaltrials.euctis registryverified 2026-08-31

  • 2025-524974-41-00CTIS

    Therapeutic exploratory (Phase II) · Irritable Bowel Syndrome - Constipation · Authorised · Belgium, Spain

    euclinicaltrials.euctis registryverified 2026-08-31

  • 2025-522640-41-00CTIS

    Therapeutic exploratory (Phase II) · Uncontrolled moderate to severe asthma · Authorised · Germany, France, Netherlands, Poland

    euclinicaltrials.euctis registryverified 2026-09-15

  • NCT07759245ClinicalTrials.gov

    PHASE2 · Pulmonary Disease, Chronic Obstructive · RECRUITING · Argentina, Austria, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-09-28

  • NCT07219953ClinicalTrials.gov

    PHASE3 · Alcohol Use Disorder · RECRUITING · Belgium, China, Germany, Japan, South Korea, Taiwan, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-11-07

  • NCT07219966ClinicalTrials.gov

    PHASE3 · Alcohol Use Disorder · RECRUITING · Belgium, China, Germany, Japan, South Korea, Taiwan, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-09-28

  • NCT07545772ClinicalTrials.gov

    PHASE2 · Irritable Bowel Syndrome; Constipation · RECRUITING · Belgium, Canada, China, Japan, Mexico, Spain, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-09-28

  • NCT07545759ClinicalTrials.gov

    PHASE2 · Irritable Bowel Syndrome; Diarrhea · RECRUITING · Belgium, Canada, China, Germany, Japan, Mexico, Poland, Spain, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-09-28

  • NCT07219173ClinicalTrials.gov

    PHASE2 · Asthma · RECRUITING · Argentina, Brazil, Canada, China, France, Germany, India, Japan, Mexico, Netherlands, Poland, United States

    clinicaltrials.govctgov registryverified 2026-11-07

  • NCT07420283ClinicalTrials.gov

    PHASE2 · Opioid Use Disorder · RECRUITING · Canada, Puerto Rico, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-11-07

  • 2026-525480-41-00CTIS

    Therapeutic exploratory (Phase II) · Pulmonary Disease, Chronic Obstructive · Authorised · Austria, Czechia, Germany, Denmark, France, Hungary, Poland, Romania

    euclinicaltrials.euctis registryverified 2026-11-07

In the briefing

Issues tagged LILLY, the owner of this asset.

Record history